Deborah Rathjen
CEO,
Carina Biotech
Australia
Dr Rathjen is an experienced and respected leader in the biotechnology and pharmaceutical industries within Australia and internationally, and has achieved in excess of $800 million in deals including partnerships with Merck & Co., J&J, Abbott (AbbVie), Nycomed (Takeda) and Merck KGaA. An immunologist by training, Dr Rathjen has extensive R&D experience in the areas of infection and immunity, inflammation, oncology and neuroscience, covering multiple treatment modalities. Dr Rathjen has led companies in Europe, US and Australia.
Sessions
-
26-Feb-2024Carina Biotech Limited
)
){kind=logo}
)
){kind=logo}
){kind=logo}